Skip to main content

Table 1 Study Population and Annual Prevalence of PAP Syndrome in the USa

From: Prevalence and healthcare burden of pulmonary alveolar proteinosis

Study year Total patientsb Total PAP patientsc Total PAP prevalence per million patientsd
 2008 15,519,985 105 6.77
 2009 15,686,604 127 8.10
 2010 16,070,700 103 6.41
 2011 15,764,422 109 6.91
 2012 16,515,902 102 6.18
 Mean 15,911,523 109 6.87
Study year Total female patientsb Female PAP patientsc PAP prevalence per million female patientse
 2008 7,953,672 51 6.41
 2009 8,038,763 67 8.33
 2010 8,233,635 57 6.92
 2011 8,069,748 67 8.30
 2012 8,427,886 59 7.00
 Mean 8,144,741 60 7.39
Study year Total male patientsb Male PAP patientsc PAP prevalence per million male patientsf
 2008 7,566,313 54 7.14
 2009 7,647,841 60 7.85
 2010 7,837,065 46 5.87
 2011 7,694,674 42 5.46
 2012 8,088,016 43 5.32
 Mean 7,766,782 49 6.31
  1. Definition of abbreviations: PAP pulmonary alveolar proteinosis
  2. aPatients are individuals represented by de-identified data in the OptumInsight database during the study period meeting the inclusion and exclusion criteria as defined in the methods
  3. bIncludes all (or female/male patients as indicated) with complete annual claims data for at least two consecutive years
  4. cIncludes all (or female/male patients as indicated) patients with at least one claim associated with an ICD-9516.0 code in the respective calendar year
  5. dCalculated as the number of PAP patients in each year divided by the total number of patients included in that year
  6. eCalculated as the number of female PAP patients in each year divided by the number of female patients included in that year
  7. fCalculated as the number of male PAP patients in each year divided by the number of male patients included in that year